{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:43:45Z","timestamp":1791960225647,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2002,4,23]]},"DOI":"10.1212\/wnl.58.8.1261","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T14:00:48Z","timestamp":1336917648000},"page":"1261-1265","source":"Crossref","is-referenced-by-count":48,"title":["Field-specific visual-evoked potentials"],"prefix":"10.1212","volume":"58","author":[{"given":"G. F.A.","family":"Harding","sequence":"first","affiliation":[{"name":"From the Neurosciences Research Institute (Dr. Harding, E.L. Spencer, and M. Conway), Aston University, Birmingham, UK; Department of Optometry and Vision Sciences (Dr. Wild), Cardiff University, Cardiff, UK; and Aventis Pharma (Dr. Bohn), Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Spencer","sequence":"additional","affiliation":[{"name":"From the Neurosciences Research Institute (Dr. Harding, E.L. Spencer, and M. Conway), Aston University, Birmingham, UK; Department of Optometry and Vision Sciences (Dr. Wild), Cardiff University, Cardiff, UK; and Aventis Pharma (Dr. Bohn), Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Wild","sequence":"additional","affiliation":[{"name":"From the Neurosciences Research Institute (Dr. Harding, E.L. Spencer, and M. Conway), Aston University, Birmingham, UK; Department of Optometry and Vision Sciences (Dr. Wild), Cardiff University, Cardiff, UK; and Aventis Pharma (Dr. Bohn), Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Conway","sequence":"additional","affiliation":[{"name":"From the Neurosciences Research Institute (Dr. Harding, E.L. Spencer, and M. Conway), Aston University, Birmingham, UK; Department of Optometry and Vision Sciences (Dr. Wild), Cardiff University, Cardiff, UK; and Aventis Pharma (Dr. Bohn), Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Bohn","sequence":"additional","affiliation":[{"name":"From the Neurosciences Research Institute (Dr. Harding, E.L. Spencer, and M. Conway), Aston University, Birmingham, UK; Department of Optometry and Vision Sciences (Dr. Wild), Cardiff University, Cardiff, UK; and Aventis Pharma (Dr. Bohn), Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7075.180"},{"key":"e_1_3_2_3_2","first-page":"1694.","volume":"314","year":"1997","unstructured":"Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible mechanisms exist. BMJ . 1997; 314: 1694.","journal-title":"BMJ"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.814"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.6.1201"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90345-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.6.716"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb01599.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.2082"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.49299.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.28600.x"},{"key":"e_1_3_2_13_2","first-page":"262","volume":"42","year":"2001","unstructured":"Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia . 2001; 42: 262\u2013267.","journal-title":"Epilepsia"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073891006002101"},{"key":"e_1_3_2_15_2","first-page":"16","volume":"61","year":"1989","unstructured":"Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract . 1989; 61: 16\u201323.","journal-title":"Br J Clin Pract"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03463.x"},{"key":"e_1_3_2_17_2","first-page":"S23","volume":"30","year":"1989","unstructured":"Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P. Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia . 1989; 30 (suppl 3): S23\u2013S25.","journal-title":"Epilepsia"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01674.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01661.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.3.347"},{"key":"e_1_3_2_21_2","first-page":"171P.","volume":"518","year":"1999","unstructured":"Harding GFA, Robertson K, Holliday I, Jones L. Field-specific visual evoked potentials for assessment of peripheral field defect in a paediatric population. J Physiol . 1999; 518P: 171P.Abstract.","journal-title":"J Physiol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00117.x"},{"key":"e_1_3_2_23_2","first-page":"179","volume":"97","year":"1999","unstructured":"Harding GFA, Robertson KA, Edson AS, Barnes P, Wild JM. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol . 1999; 97: 179\u2013188.","journal-title":"Doc Ophthalmol"},{"key":"e_1_3_2_24_2","first-page":"291","volume":"91","year":"1996","unstructured":"Marmor MF, Holder GE, Porciatti V, Trick GL, Zrenner E. Guidelines for basic pattern electroretinography. Doc Ophthalmol . 1996; 91: 291\u2013298.","journal-title":"Doc Ophthalmol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Harding GFA Robertson KA Holliday I. Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population. In: Ambler Z Nevs\u00edmalov\u00e1 S Kadaka Z Rossini PM eds. Clinical neurophysiology at the beginning of the 21st century. Clin Neurophysiol 2000;53(suppl):323\u2013330.","DOI":"10.1016\/S1567-424X(09)70175-8"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.58.8.1261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:50:15Z","timestamp":1711648215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.58.8.1261"}},"subtitle":["Identifying field defects in vigabatrin-treated children"],"short-title":[],"issued":{"date-parts":[[2002,4,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,4,23]]}},"alternative-id":["10.1212\/WNL.58.8.1261"],"URL":"https:\/\/doi.org\/10.1212\/wnl.58.8.1261","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,23]]}}}